• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

直面争议：白细胞介素-6 与 COVID-19 细胞因子风暴综合征。

Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.

机构信息

Division of Hematology, Dept of Medicine, University of British Columbia, Vancouver, BC, Canada

Centre for Health Education Scholarship, University of British Columbia, Vancouver, BC, Canada.

出版信息

Eur Respir J. 2020 Oct 1;56(4). doi: 10.1183/13993003.03006-2020. Print 2020 Oct.

DOI:10.1183/13993003.03006-2020
PMID:32883678
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7474149/
Abstract

https://bit.ly/3jq3uJ4

摘要

链接

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c208/7474149/ed104fa8c02a/ERJ-03006-2020.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c208/7474149/ebfa589fcef6/ERJ-03006-2020.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c208/7474149/ed104fa8c02a/ERJ-03006-2020.02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c208/7474149/ebfa589fcef6/ERJ-03006-2020.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c208/7474149/ed104fa8c02a/ERJ-03006-2020.02.jpg

相似文献

1
Confronting the controversy: interleukin-6 and the COVID-19 cytokine storm syndrome.直面争议：白细胞介素-6 与 COVID-19 细胞因子风暴综合征。
Eur Respir J. 2020 Oct 1;56(4). doi: 10.1183/13993003.03006-2020. Print 2020 Oct.
2
Audio Interview: Tocilizumab and Covid-19.音频访谈：托珠单抗与新冠病毒
N Engl J Med. 2020 Oct 22;383(17):e114. doi: 10.1056/NEJMe2032051.
3
COVID-19: Some clinical questions after the first 4 months.新冠病毒病（COVID-19）：最初4个月后的一些临床问题
Eur J Clin Invest. 2020 Jul;50(7):e13326. doi: 10.1111/eci.13326. Epub 2020 Jul 5.
4
The COVID-19 Cytokine Storm; What We Know So Far.《COVID-19 细胞因子风暴：目前我们所了解的》。
Front Immunol. 2020 Jun 16;11:1446. doi: 10.3389/fimmu.2020.01446. eCollection 2020.
5
Interleukin-6 and severe COVID-19: a systematic review and meta-analysis.白细胞介素-6 与重症 COVID-19：系统评价和荟萃分析。
Eur Cytokine Netw. 2020 Jun 1;31(2):44-49. doi: 10.1684/ecn.2020.0448.
6
Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.托珠单抗治疗的 2019 冠状病毒病成年患者的临床特征和生存预测因素。
J Autoimmun. 2020 Nov;114:102512. doi: 10.1016/j.jaut.2020.102512. Epub 2020 Jul 3.
7
Targeting inflammation and cytokine storm in COVID-19.针对新型冠状病毒肺炎中的炎症和细胞因子风暴
Pharmacol Res. 2020 Sep;159:105051. doi: 10.1016/j.phrs.2020.105051. Epub 2020 Jun 27.
8
Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.新型冠状病毒肺炎相关细胞因子风暴综合征的改善：与嵌合抗原受体T细胞细胞因子释放综合征的相似之处
Br J Haematol. 2020 Aug;190(3):e150-e154. doi: 10.1111/bjh.16961. Epub 2020 Jul 16.
9
IL-6: Relevance for immunopathology of SARS-CoV-2.白细胞介素 6：与 SARS-CoV-2 免疫病理学的相关性。
Cytokine Growth Factor Rev. 2020 Jun;53:13-24. doi: 10.1016/j.cytogfr.2020.05.009. Epub 2020 May 20.
10
After 62 years of regulating immunity, dexamethasone meets COVID-19.地塞米松调控免疫 62 年后迎击 COVID-19。
Nat Rev Immunol. 2020 Oct;20(10):587-588. doi: 10.1038/s41577-020-00421-x.

引用本文的文献

1
Randomized adaptive assessment of post COVID syndrome treatments (RAPID): a study protocol for a multicenter, randomized, controlled adaptive platform trial of treatment options for Post Covid Syndrome (PCS) on patients physical function including the first intervention specific appendix RAPID_REVIVE (reducing inflammatory activity in patients with PCS).新冠后综合征治疗的随机适应性评估（RAPID）：一项针对新冠后综合征（PCS）患者身体功能治疗方案的多中心、随机、对照适应性平台试验的研究方案，包括首个特定干预附录RAPID_REVIVE（降低PCS患者的炎症活动）。
Trials. 2025 Aug 19;26(1):297. doi: 10.1186/s13063-025-09008-0.
2
Hematologic and Immunologic Overlap Between COVID-19 and Idiopathic Pulmonary Fibrosis.新型冠状病毒肺炎与特发性肺纤维化之间的血液学和免疫学重叠
J Clin Med. 2025 Jul 24;14(15):5229. doi: 10.3390/jcm14155229.
3

本文引用的文献

1
The Association of Inflammatory Cytokines in the Pulmonary Pathophysiology of Respiratory Failure in Critically Ill Patients With Coronavirus Disease 2019.2019冠状病毒病危重症患者呼吸衰竭肺病理生理学中炎性细胞因子的关联
Crit Care Explor. 2020 Sep 17;2(9):e0203. doi: 10.1097/CCE.0000000000000203. eCollection 2020 Sep.
2
Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia.新型冠状病毒肺炎肺血管内凝血病变的免疫机制
Lancet Rheumatol. 2020 Jul;2(7):e437-e445. doi: 10.1016/S2665-9913(20)30121-1. Epub 2020 May 7.
3
A dynamic COVID-19 immune signature includes associations with poor prognosis.
A genetic algorithm-based ensemble model for efficiently identifying interleukin 6 inducing peptides.一种基于遗传算法的集成模型，用于高效识别白细胞介素6诱导肽。
Sci Rep. 2025 Jul 1;15(1):21213. doi: 10.1038/s41598-025-05491-2.
4
The ACE2 decoy receptor can overcome immune escape by rapid mutating SARS-CoV-2 variants and reduce cytokine induction and clot formation.血管紧张素转换酶2（ACE2）诱饵受体可以通过快速突变的严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体克服免疫逃逸，并减少细胞因子诱导和血栓形成。
J Biomed Sci. 2025 Jun 26;32(1):59. doi: 10.1186/s12929-025-01156-4.
5
Impact of SARS-CoV-2 Wuhan and Omicron Variant Proteins on Type I Interferon Response.严重急性呼吸综合征冠状病毒2型武汉株和奥密克戎变异株蛋白对I型干扰素反应的影响。
Viruses. 2025 Apr 15;17(4):569. doi: 10.3390/v17040569.
6
ABO blood group and COVID-19 severity: Associations with endothelial and adipocyte activation in critically ill patients.ABO血型与新冠病毒病严重程度：与危重症患者内皮细胞和脂肪细胞激活的关联
PLoS One. 2025 Apr 2;20(4):e0320251. doi: 10.1371/journal.pone.0320251. eCollection 2025.
7
MEFV gene variations in COVID-19 pneumonia patients (Pilot study).新冠肺炎患者的MEFV基因变异（初步研究）
J Genet Eng Biotechnol. 2025 Mar;23(1):100473. doi: 10.1016/j.jgeb.2025.100473. Epub 2025 Mar 4.
8
Design of quinoline SARS-CoV-2 papain-like protease inhibitors as oral antiviral drug candidates.喹啉类新型冠状病毒木瓜样蛋白酶抑制剂作为口服抗病毒候选药物的设计
Nat Commun. 2025 Feb 13;16(1):1604. doi: 10.1038/s41467-025-56902-x.
9
The role of C-reactive protein and ferritin in the diagnosis of HLH, adult-onset still's disease, and COVID-19 cytokine storm.C反应蛋白和铁蛋白在噬血细胞性淋巴组织细胞增生症、成人斯蒂尔病及新型冠状病毒肺炎细胞因子风暴诊断中的作用
Sci Rep. 2024 Dec 28;14(1):31306. doi: 10.1038/s41598-024-82760-6.
10
Peripheral lncRNA NEAT-1, miR374b-5p, and IL6 panel to guide in COVID-19 patients' diagnosis and prognosis.外周lncRNA NEAT-1、miR374b-5p和IL6检测指标用于指导COVID-19患者的诊断和预后。
PLoS One. 2024 Dec 27;19(12):e0313042. doi: 10.1371/journal.pone.0313042. eCollection 2024.
一个动态的 COVID-19 免疫特征包括与预后不良的关联。
Nat Med. 2020 Oct;26(10):1623-1635. doi: 10.1038/s41591-020-1038-6. Epub 2020 Aug 17.
4
Longitudinal analyses reveal immunological misfiring in severe COVID-19.纵向分析揭示了重症 COVID-19 中的免疫失调。
Nature. 2020 Aug;584(7821):463-469. doi: 10.1038/s41586-020-2588-y. Epub 2020 Jul 27.
5
IL-6-based mortality risk model for hospitalized patients with COVID-19.基于 IL-6 的 COVID-19 住院患者死亡风险模型。
J Allergy Clin Immunol. 2020 Oct;146(4):799-807.e9. doi: 10.1016/j.jaci.2020.07.009. Epub 2020 Jul 22.
6
Dexamethasone in Hospitalized Patients with Covid-19.地塞米松在 COVID-19 住院患者中的应用。
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
7
Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study.新型冠状病毒肺炎相关凝血病中的内皮病变：来自一项单中心横断面研究的证据
Lancet Haematol. 2020 Aug;7(8):e575-e582. doi: 10.1016/S2352-3026(20)30216-7. Epub 2020 Jun 30.
8
Is a "Cytokine Storm" Relevant to COVID-19?“细胞因子风暴”与新冠病毒病有关吗？
JAMA Intern Med. 2020 Sep 1;180(9):1152-1154. doi: 10.1001/jamainternmed.2020.3313.
9
Amelioration of COVID-19-related cytokine storm syndrome: parallels to chimeric antigen receptor-T cell cytokine release syndrome.新型冠状病毒肺炎相关细胞因子风暴综合征的改善：与嵌合抗原受体T细胞细胞因子释放综合征的相似之处
Br J Haematol. 2020 Aug;190(3):e150-e154. doi: 10.1111/bjh.16961. Epub 2020 Jul 16.
10
COVID-19-associated coagulopathy: An exploration of mechanisms.COVID-19 相关凝血功能障碍：机制探索。
Vasc Med. 2020 Oct;25(5):471-478. doi: 10.1177/1358863X20932640. Epub 2020 Jun 19.